Can BMS Deliver on Innovation?
In December of 2007, Bristol-Myers announced its commitment to become a 'next-generation" biopharma company, with a focus on biologics and specialty drugs. That meant it would divest its non-core non-pharma assets, improve productivity, bolster R&D, and make sure its financing was in shape-even as its peers were taking the opposite approach. Two years later, it appears to be successfully executing on its objectives for the first two stages.
You may also be interested in...
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
Four years ago, Bristol management changed course and established the company as a pure play biopharma. Now, with the launch of Yervoy for metastatic melanoma and a late-stage pipeline that is chock-full, the strategy appears about to pay off. CEO Lamberto Andreotti and R&D president Elliott Sigal talked with IN VIVO about the launch of Yervoy and how Bristol, relying on R&D productivity, not diversification, is on track to overcome the extensive patent losses ahead.